California State Teachers Retirement System Sells 12,330 Shares of Becton, Dickinson and Company $BDX

California State Teachers Retirement System decreased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.5% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 473,355 shares of the medical instruments supplier’s stock after selling 12,330 shares during the period. California State Teachers Retirement System’s holdings in Becton, Dickinson and Company were worth $74,426,000 as of its most recent SEC filing.

Several other large investors have also added to or reduced their stakes in the stock. Crux Wealth Advisors grew its stake in Becton, Dickinson and Company by 0.8% during the fourth quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after acquiring an additional 49 shares in the last quarter. Larson Financial Group LLC lifted its stake in Becton, Dickinson and Company by 1.7% in the 4th quarter. Larson Financial Group LLC now owns 3,230 shares of the medical instruments supplier’s stock worth $627,000 after purchasing an additional 53 shares in the last quarter. Camelot Portfolios LLC boosted its holdings in Becton, Dickinson and Company by 1.5% in the 4th quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock valued at $688,000 after purchasing an additional 54 shares during the period. McElhenny Sheffield Capital Management LLC boosted its holdings in Becton, Dickinson and Company by 3.6% in the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock valued at $309,000 after purchasing an additional 55 shares during the period. Finally, Atlantic Union Bankshares Corp grew its position in shares of Becton, Dickinson and Company by 0.9% during the 4th quarter. Atlantic Union Bankshares Corp now owns 6,108 shares of the medical instruments supplier’s stock valued at $1,185,000 after purchasing an additional 57 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BDX shares. Piper Sandler decreased their price target on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Stifel Nicolaus dropped their price objective on Becton, Dickinson and Company from $215.00 to $175.00 in a research note on Thursday, May 7th. Bank of America reduced their target price on Becton, Dickinson and Company from $177.00 to $170.00 in a research report on Friday, June 12th. The Goldman Sachs Group decreased their target price on Becton, Dickinson and Company from $156.00 to $150.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 27th. Finally, Royal Bank Of Canada set a $175.00 price target on Becton, Dickinson and Company in a research report on Tuesday, April 14th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $180.93.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $165.59 on Friday. The company has a current ratio of 0.94, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The firm has a market capitalization of $45.63 billion, a PE ratio of 41.92, a price-to-earnings-growth ratio of 12.00 and a beta of 0.21. The business’s 50-day moving average price is $151.48 and its 200-day moving average price is $163.63. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $187.35.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.13. The company had revenue of $4.71 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and Company had a return on equity of 15.37% and a net margin of 5.33%.Becton, Dickinson and Company’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.35 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 12.53 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Wednesday, September 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.5%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 106.33%.

Insider Buying and Selling

In related news, EVP Michael David Garrison sold 1,100 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $145.66, for a total value of $160,226.00. Following the transaction, the executive vice president owned 13,172 shares in the company, valued at $1,918,633.52. This trade represents a 7.71% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Thomas E. Polen, Jr. sold 2,764 shares of the business’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $146.35, for a total transaction of $404,511.40. Following the completion of the sale, the chief executive officer directly owned 110,163 shares of the company’s stock, valued at $16,122,355.05. This represents a 2.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 5,189 shares of company stock valued at $765,661. Company insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.